By Lauren Hirsch, Olivia Oran and Carl O'Donnell (Reuters) – U.S. drugmaker Pfizer Inc is evaluating a potential sale or spin-off of its consumer health division that could value the unit at as much as $14 billion, people familiar with the matter said on Wednesday. A Pfizer exit from the consumer health business, which includes lip balm Chapstick and painkiller Advil, would be one of its biggest corporate moves since abandoning a $160 billion deal to buy Irish drugmaker Allergan Inc earlier this year. The deliberations are still in a preliminary stage and the New York-based pharmaceutical company may opt to retain the business, the people said.
Read the original here:
Exclusive: Pfizer weighs sale or spin-off of consumer health unit – sources
